The PepTivator
®
EBV EBNA-1 is a peptide pool that consists mainly of 15-mer peptides with 11 amino acids overlap, covering the complete sequence of the Epstein-Barr virus EBNA-1 protein (UniProt ID: P03211).
PepTivator peptide pools have been developed for the efficient
in vitro
stimulation of antigen–specific CD4
+
and CD8
+
T cells, as peptides of 15-aa length with 11 aa overlap represent an optimized solution for stimulating both CD4
+
and CD8
+
T cells in various applications.
1
Quantitative, phenotypical, or functional analysis of EBV EBNA-1–specific T cell immunity can provide important information on the

Data and images for
PepTivator
®
EBV EBNA-1
, human

Figures

Figure 1

View details
Production of IFN-γ by human CD4
+
or CD8
+
T cells after stimulation with different antigens using PepTivator Peptide Pools. Data from two different donors are shown (triplicates).

Figure 1

Production of IFN-γ by human CD4
+
or CD8
+
T cells after stimulation with different antigens using PepTivator Peptide Pools. Data from two different donors are shown (triplicates).

Specifications for
PepTivator
®
EBV EBNA-1
, human

Overview

The PepTivator
®
EBV EBNA-1 is a peptide pool that consists mainly of 15-mer peptides with 11 amino acids overlap, covering the complete sequence of the Epstein-Barr virus EBNA-1 protein (UniProt ID: P03211).
PepTivator peptide pools have been developed for the efficient
in vitro
stimulation of antigen–specific CD4
+
and CD8
+
T cells, as peptides of 15-aa length with 11 aa overlap represent an optimized solution for stimulating both CD4
+
and CD8
+
T cells in various applications.
1
Quantitative, phenotypical, or functional analysis of EBV EBNA-1–specific T cell immunity can provide important information on the natural course of immune responses in healthy or immunocompromised individuals.
PepTivator EBV EBNA-1-HT is a peptide pool lyophilized in the wells of a 96-well plate, allowing stimulation and analysis of cells directly on the plate.
The convenient 96-well format, composed of 12 individually removable strips of 8 wells each allows for easy and flexible experimental set-up, different antigens can be combined by assembling different strips. A control can also be added easily by using strips from the Control plate (12x8).

Detailed product information

Background information

Epstein-Barr virus (EBV) is a human γ-herpes virus with B cell growth–transforming ability and lymphomagenic potential. More than 90% of human adults are infected with EBV. Usually the primary infection is asymptomatic, but some individuals develop an infectious mononucleosis, a self-limiting lymphoproliferative disease. The Epstein-Barr nuclear antigen 1 (EBNA-1) protein is involved in the replication of viral episomes and therefore crucial for the persistence of the infection. Its expression is maintained in all latency cycles of infection and in all EBV-associated malignancies. EBNA-1-specific CD4
+
and CD8
+
T cells have been found in EBV-infected individuals.
2–5

Downstream applications

The
in vitro
stimulation of EBV EBNA-1–specific CD4
+
and CD8
+
T cells with PepTivator EBV EBNA-1 causes the secretion of effector cytokines and the upregulation of activation markers, which then allow the detection and isolation of EBV EBNA-1–specific T cells
6
:
  • Detection and analysis of EBV EBNA-1–specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
  • Isolation of viable EBV EBNA-1–specific CD4+ T cells with the CD154 MicroBead Kit, or of CD4+ and CD8+ T cells using the CD137 MicroBead Kit or MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
  • Generation of EBV EBNA-1–specific CD4+ and CD8+ effector/memory T cells from naive T cell populations for research on immunotherapy and vaccination
  • Pulsing of antigen-presenting cells, for example, for research on dendritic cell vaccination.

References for
PepTivator
®
EBV EBNA-1
, human

Publications

  1. Kiecker, F. et al. (2004) Analysis of antigen-specific T-cell responses with synthetic peptides--what kind of peptide for which purpose? Hum. Immunol. 65: 523-536
  2. Paludan, C. et al. (2002) Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J. Immunol. 169: 1593-1603
  3. Voo, K. S. et al. (2004)
    Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8
    +
    T lymphocytes.
    J. Exp. Med. 199: 459-470
  4. Long, H. M. et al. (2005) CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J. Virol. 79: 4896-4907
  5. Dodero A. et al. (2009) Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 113: 4771-4779

Related products for
PepTivator
®
EBV EBNA-1
, human

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?